Stockscreener 앱 받기
42.79
3.60%
-1.60
시간 외 거래:
42.54
-0.25
-0.58%
전일 마감가:
$44.39
열려 있는:
$45.75
하루 거래량:
60.88M
Relative Volume:
2.08
시가총액:
$9.31B
수익:
$1.78B
순이익/손실:
$164.40M
주가수익비율:
62.01
EPS:
0.69
순현금흐름:
$236.51M
1주 성능:
-9.19%
1개월 성능:
-18.56%
6개월 성능:
+4.83%
1년 성능:
+106.12%
1일 변동 폭
$42.40
$48.34
1주일 범위
$42.40
$48.45
52주 변동 폭
$19.15
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
명칭
Hims Hers Health Inc
전화
415-851-0195
주소
2269 CHESTNUT ST, SAN FRANCISCO
HIMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
42.79 | 10.03B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
124.46 | 63.97B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.56 | 42.40B | 29.63B | 260.53M | 4.77B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.32 | 41.77B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.46 | 23.54B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
437.33 | 18.89B | 3.08B | 1.24B | 1.07B | 25.61 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-04 | 재확인 | Needham | Buy |
| 2025-04-29 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2025-01-07 | 개시 | BTIG Research | Buy |
| 2024-12-17 | 개시 | Morgan Stanley | Overweight |
| 2024-11-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-08-22 | 개시 | Needham | Buy |
| 2024-08-09 | 다운그레이드 | Imperial Capital | Outperform → In-line |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-04-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-10 | 개시 | Canaccord Genuity | Buy |
| 2024-02-28 | 업그레이드 | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2023-12-07 | 개시 | Imperial Capital | In-line |
| 2023-07-28 | 개시 | TD Cowen | Outperform |
| 2023-04-11 | 개시 | Robert W. Baird | Neutral |
| 2023-02-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-08 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-07-15 | 개시 | SVB Leerink | Underperform |
| 2022-04-14 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | Deutsche Bank | Hold |
| 2021-12-02 | 개시 | Jefferies | Hold |
| 2021-11-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 개시 | BofA Securities | Neutral |
| 2021-05-20 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 개시 | Truist | Hold |
| 2021-03-09 | 개시 | Credit Suisse | Neutral |
| 2021-03-02 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-02-17 | 개시 | Citigroup | Neutral |
| 2021-02-12 | 개시 | Piper Sandler | Neutral |
| 2021-02-08 | 개시 | Tigress Financial | Buy |
모두보기
Hims Hers Health Inc 주식(HIMS)의 최신 뉴스
White House nears deal to lower prices for weight loss drugs Wegovy and Zepbound - AOL.com
Best Healthcare Stocks To Follow TodayNovember 4th - MarketBeat
OMCL vs. HIMS: Which Stock Is the Better Value Option? - sharewise.com
Hims & Hers Eyes Major Weight-Loss Breakthrough With Potential Novo Nordisk Wegovy Deal - Yahoo Finance
Hims & Hers gains as analysts welcome talks with Novo for Wegovy sales - MSN
Deutsche Bank Adjusts Hims & Hers Health Price Target to $42 From $48, Maintains Hold Rating - MarketScreener
HIMS Q3 Deep Dive: Personalized Offerings and Strategic Expansion Shape Telehealth Growth - TradingView
Hims & Hers rises after Q3 revenue beat - TradingView
BTIG Research Reiterates Buy Rating for Hims & Hers Health (NYSE:HIMS) - MarketBeat
Hims & Hers Health (NYSE:HIMS) Price Target Raised to $32.00 - MarketBeat
Hims and Hers tops revenue estimates as telehealth provider attracts more users - MSN
Earnings live: Palantir stock rises modestly on strong results, Hims & Hers stock surges - Yahoo Finance
Hims Shares Rise on Talks to Offer Novo’s New Obesity Pill - Yahoo Finance
Biggest stock movers Tuesday: PLTR, SRPT, and more - MSN
Hims & Hers Plunges After Novo Split, Eyes Global Push - Value The Markets
Hims & Hers Stock (HIMS) Soars on Potential Deal to Offer Novo Nordisk’s Wegovy - TipRanks
Decoding Hims & Hers Health Inc (HIMS): A Strategic SWOT Insight - GuruFocus
Hims & Hers Health Inc (HIMS) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance
Hims & Hers Health Reports Strong Q3 2025 Growth - TipRanks
Palantir, Kimberly-Clark, Hims & Hers, Navitas And Cipher Mining: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Key facts: Novo Nordisk Q3 revenue up 9.4%; bids $8.5B for Metsera; Hims launches semaglutide - TradingView
Hims Hers (HIMS) Q3 2025 Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Hims & Hers Health Q3 2025 misses EPS, stock rebounds - Investing.com Philippines
Novo Nordisk’s weight-loss drug Wegovy could soon have a new sales outlet in the U.S. - MarketWatch
Hims & Hers Health (HIMS) Surges After Hours on Robust Q3 and Renewed Novo Nordisk (NVO) Wegovy Talks - FinancialContent
Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates - Yahoo! Finance Canada
Hims & Hers Health in discussions with Novo Nordisk to sell Wegovy - Seeking Alpha
Hims & Hers in talks to offer Novo’s new obesity pill - Modern Healthcare
Hims & Hers Health Third-Quarter Revenue Jumps as Subscribers Grow - The Wall Street Journal
Hims & Hers Health Q3 revenue tops estimates as subscriber growth jumps - Investing.com Philippines
Hims & Hers Health rises after narrowing 2025 EBITDA guidance, Q3 EPS miss - Seeking Alpha
After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina - Investing.com Canada
Hims & Hers Health (NYSE:HIMS) Issues Quarterly Earnings Results, Meets Expectations - MarketBeat
Hims & Hers Health Q3 revenue tops estimates as subscriber growth jumps By Investing.com - Investing.com South Africa
Hims and Hers beats revenue estimates on strong subscriber growth - Yahoo Finance
Hims & Hers Q3 2025 Earnings: Revenue Beats Forecasts on Subscriber GrowthNews and Statistics - IndexBox
Hims & Hers Stock Pops After Q3 Earnings: Here's WhyHims & Hers Health (NYSE:HIMS) - Benzinga
Hims and Hers up after beating quarterly revenue estimates - TradingView
Hims & Hers Health’s (NYSE:HIMS) Q3 Sales Top Estimates - Yahoo Finance
Stock Market Today: Palantir, Vertex, and Hims & Hers Report After the Closing Bell - TheStreet
Hims and Hers misses quarterly profit estimates - Yahoo! Finance Canada
Hims rises on revenue beat, discloses it’s again in partnership talks with Novo - Sherwood News
How we’re reaching more customers with a new standard of care - Hims & Hers Newsroom
Hims and Hers Beats Revenue Estimates on Strong Subscriber Growth - US News Money
Earnings Flash (HIMS) Hims & Hers Health, Inc. Reports Q3 Revenue $599.0M, vs. FactSet Est of $580.2M - MarketScreener
Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results - The Joplin Globe
Notable Monday Option Activity: PFGC, GRPN, HIMS - Nasdaq
Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets - Stocktwits
Hims & Hers Q3 Preview: GLP-1 Drug Expansion Draws Investor Focus - Stocktwits
OMCL vs. HIMS: Which Stock Should Value Investors Buy Now? - Yahoo Finance
PREVIEW: Hims & Hers dips; focus on weigth-loss drug - TradingView
Hims Hers Health Inc (HIMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.53%
0.45%
자본화:
|
볼륨(24시간):